Search for Clinical Trial Results

Sponsored By

Kennedy Disease - 17 Studies Found

Status Study
Active, not recruiting Study Name: Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
Condition: Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Date: 2013-06-26
Interventions: Drug: Enzalutamide 160 mg administered as four soft gelatin capsules orally once daily
Completed Study Name: Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors
Condition: Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
Date: 2014-04-29
Interventions: Drug: AZD5312 AZD5312 is a generation 2.5 antisense oligonucleotide (ASO) which is designed with the pur
Terminated Study Name: A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)
Condition:
  • Metastatic Breastcancer
  • Estrogen Receptor Positive Breast Cancer
  • Androgen Receptor Positive
  • Estrogen Receptor Negative
  • Date: 2016-11-21
    Interventions:
    • Drug: Enobosarm Given PO
Recruiting Study Name: A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer
Condition: Prostate Cancer
Date: 2015-07-06
Interventions:
  • Drug: LY2452473 LY2452473 is a
Not yet recruiting Study Name: Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
Condition:
  • Castration-Resistant Prostatic Cancer
  • Metastatic Prostate Carcinoma
  • Biological: GnRH agonist/antagonist

Completed Study Name: Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women
Condition:
  • Libido
  • Receptors, Androgen
  • Polymorphism, Genetic
  • Date: 2013-10-30
Recruiting Study Name: Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
Condition: Salivary Cancer
Date: 2016-04-21
Interventions: Drug: enzalutamide oral
Withdrawn Study Name: STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling
Condition: Adenocarcinoma of the Prostate
Date: 2011-04-21
Interventions:
  • Drug: STA9090 200 mg/m^2 IV ev
Recruiting Study Name: Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Condition: Metastatic Breast Cancer
Date: 2013-11-08
Interventions: Drug: Orteronel Other Name: Tak-700
Next >>>